Compare GSK plc (GSK) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.7 (market cap $7.77B). The key difference: GSK plc is far larger — about 11.8× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and GSK plc pays a 3.9% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| GSK | PDBC | |
|---|---|---|
Market Cap | $91.88B | $7.77B |
Volume | 7,730,529 | 6,100,303 |
Sector | Health | — |
52-Week High | $61.18 | $20.10 |
52-Week Low | $43.24 | $13.16 |
Typical Hold Time | 93 Days | 56 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
PDBC (Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF) trades at $19.66, up 1.29% with strong bullish technical signals from moving averages. The ETF has delivered impressive performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows mixed sentiment with significant short interest growth of 215.4% in September offset by multiple institutional purchases.
The commodity ETF outlook remains positive given ongoing geopolitical risks and defensive sector rotation, though elevated short interest and overbought RSI readings suggest near-term consolidation risk. Commodity super-squeeze warnings from HSBC highlight potential upside while defensive ETF inflows support continued institutional demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
